In the field of Regenerative Medicine, the preclinical and clinical research on multipotent adult stem cells, and in ...

Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral ...

In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food ...

NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Rising demand for mesenchymal stem cell (MSC)-based therapies, coupled with expanding applications in regenerative medicine, immunotherapy, and tissue ...

Figure 1: Immunomodulatory effects of simulated MSCs. MSCs utilize different molecular mechanisms to suppress (in most cases) or activate immune cells. Orange arrows: inhibition; Green arrows: ...

Longeveron receives Japanese patent for potency assay methods to assess human mesenchymal stem cells: Miami Saturday, January 31, 2026, 13:00 Hrs [IST] Longeveron Inc, a clinical ...

A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and ...

The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.

BioCardia, Inc. announced the completion of enrollment and dosing in the low dose cohort of its Phase I/II CardiALLO™ trial, which aims to treat patients with ischemic heart failure of reduced ...